Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Sionna Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Sionna Therapeutics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 7:17 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033876
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $18,963 | $13,668 |
| General and administrative | 10,636 | 5,991 |
| Total operating expenses | 29,599 | 19,659 |
| Loss from operations | (29,599) | (19,659) |
| Other income: | ||
| Interest income | 2,820 | 3,000 |
| Other income | — | 177 |
Item 1. Financial Statements
FAQ
- What is Sionna Therapeutics's R&D?
- Sionna Therapeutics (SION) reported R&D of $18.96M in Q1 2026.
- How has Sionna Therapeutics's R&D changed year-over-year?
- Sionna Therapeutics's R&D increased by 38.7% year-over-year, from $13.67M to $18.96M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Sionna Therapeutics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude